doc. Mgr. Martin Trbušek, Dr.

2013

• Ofatumumab added to dexamethasone in patients with relapsed of refractory chronic lymphocytc leukemia. Results from a phase II study of the czech leukemia study group for life

  DOUBEK Michael BRYCHTOVÁ Yvona PANOVSKÁ Anna TRIZULJAK J. ŠEBEJOVÁ Ludmila STEHLÍKOVÁ Olga CHOVANCOVÁ Jana MALČÍKOVÁ Jitka ŠMARDOVÁ Jana PLEVOVÁ Karla VOLFOVÁ Pavlína TRBUŠEK Martin MRÁZ Marek MAJERČÁKOVÁ Denisa OBRTLÍKOVÁ Petra KARBAN Josef SMOLEJ Lukáš LINDTNEROVÁ Michaela OLTOVÁ Alexandra JELÍNKOVÁ Eva POSPÍŠILOVÁ Šárka MAYER Jiří

  Conference abstract

  Year: 2013, type: Conference abstract

• Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia

  TE RAA G. Doreen MALČÍKOVÁ Jitka POSPÍŠILOVÁ Šárka TRBUŠEK Martin MRÁZ Marek LE GARFF-TAVERNIER Maria MERLE-BERAL Helene LIN Ke PETTITT Andrew R. MERKEL Olaf STANKOVIC Tatjana VAN OERS Marinus H. ELDERING Eric STILGENBAUER Stephan ZENZ Thorsten KATER Arnon P.

  Article in Periodical

  Leukemia & Lymphoma, year: 2013, volume: 54, edition: 8, DOI

• Reactivation of selected p53 mutants in B-cell tumor cell lines using targeted small molecules

  JAŠKOVÁ Zuzana ŠEBEJOVÁ Ludmila POSPÍŠILOVÁ Šárka TRBUŠEK Martin

  Conference abstract

  Year: 2013, type: Conference abstract

• Reaktivace vybraných p53 mutantů u B-buněčných nádorových linií prostřednictvím malých cílených molekul

  JAŠKOVÁ Zuzana ŠEBEJOVÁ Ludmila POSPÍŠILOVÁ Šárka TRBUŠEK Martin

  Conference abstract

  Year: 2013, type: Conference abstract

• SF3B1 mutations frequently occur with both ATM mutations and TP53 mutations in CLL patients

  NAVRKALOVÁ Veronika MALČÍKOVÁ Jitka KANTOROVÁ Barbara ŠEBEJOVÁ Ludmila PLEVOVÁ Karla MRÁZ Marek DOUBEK Michael BRYCHTOVÁ Yvona ŠMARDOVÁ Jana MAYER Jiří POSPÍŠILOVÁ Šárka TRBUŠEK Martin

  Conference abstract

  Year: 2013, type: Conference abstract

• Synthetic lethality in p53 mutated B-cell mylignancies: Chk-1 inhibition and DNA-PK inhibition effect in cell lines and primary CLL cells

  ZEMANOVÁ Jana ŠEBEJOVÁ Ludmila PARUCH Kamil HYLSE Ondřej POSPÍŠILOVÁ Šárka MAYER Jiří TRBUŠEK Martin

  Conference abstract

  Year: 2013, type: Conference abstract

• The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.

  MALČÍKOVÁ Jitka RÁZGA Filip JURČEK Tomáš DVOŘÁKOVÁ Dana ŽÁČKOVÁ Daniela TOŠKOVÁ Hana ŠEBEJOVÁ Ludmila ŠMARDOVÁ Jana OLTOVÁ Alexandra VAŇKOVÁ Gabriela JURAČKOVÁ Lenka TRBUŠEK Martin POSPÍŠILOVÁ Šárka MAYER Jiří RÁČIL Zdeněk

  Article in Periodical

  Leukemia & Lymphoma, year: 2013, volume: 54, edition: 9, DOI

• The expression of a single microRNA -miR-34a - is a reliable marker for impairment of TP53-pathway in chronic lymphocytic leukemia

  MRÁZ Marek ČERNÁ Kateřina MUSILOVÁ Kateřina MALČÍKOVÁ Jitka PLEVOVÁ Karla PAVLOVÁ Šárka TICHÝ Boris BRYCHTOVÁ Yvona DOUBEK Michael MAYER Jiří TRBUŠEK Martin POSPÍŠILOVÁ Šárka

  Conference abstract

  Year: 2013, type: Conference abstract

• The expression of micrRNA-34a is a highly reliable for impairment of p53-pathway in CLL: development of clinically applicable assay

  MRÁZ Marek ČERNÁ Kateřina MUSILOVÁ Kateřina MALČÍKOVÁ Jitka PLEVOVÁ Karla PAVLOVÁ Šárka TICHÝ Boris BRYCHTOVÁ Yvona DOUBEK Michael MAYER Jiří TRBUŠEK Martin POSPÍŠILOVÁ Šárka

  Conference abstract

  Year: 2013, type: Conference abstract

• The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab

  PANOVSKÁ Anna SMOLEJ L. LYSÁK D. BRYCHTOVÁ Yvona ŠIMKOVIČ M. MOTYČKOVÁ M. VODÁREK P. LINDTNEROVÁ Michaela TRBUŠEK Martin MALČÍKOVÁ Jitka POSPÍŠILOVÁ Šárka MAYER Jiří DOUBEK Michael

  Article in Periodical

  European Journal of Haematology, year: 2013, volume: 90, edition: 6, DOI